Atezolizumab plus Bevacizumab as a downstaging therapy for liver transplantation in Hepatocellular carcinoma with portal vein thrombosis: The first report.
Downstaging
Hepatocellular carcinoma
Immunotherapy
Liver cancer
Liver transplantation
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
received:
10
07
2023
revised:
06
01
2024
accepted:
08
01
2024
medline:
15
1
2024
pubmed:
15
1
2024
entrez:
14
1
2024
Statut:
aheadofprint
Résumé
Atezolizumab plus bevacizumab is the preferred first-line regimen for patients with advanced Hepatocellular carcinoma (HCC). Limited data have shown promising results with the use of immune checkpoint inhibitors like nivolumab to downstage these patients for liver transplantation. Here, we describe the first case of successful downstaging with atezolizumab plus bevacizumab in a patient with Multifocal HCC and main portal vein tumoral thrombosis (PVTT) followed by ABO-incompatible live donor liver transplantation (LDLT). This illustrated case highlights that atezolizumab plus bevacizumab therapy may be a potential bridging tool for curative liver transplantation.
Identifiants
pubmed: 38219868
pii: S1600-6135(24)00072-8
doi: 10.1016/j.ajt.2024.01.007
pii:
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.